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Abstract
 Due to their role in fine-tuning cellular protein expression,Background:
microRNAs both promote viral replication and contribute to antiviral
responses, for a range of viruses. The interactions between norovirus and
the microRNA machinery have not yet been studied. Here, we investigated
the changes that occur in microRNA expression during murine norovirus
(MNV) infection.
 Using RT-qPCR-based arrays, we analysed changes in miRNAMethods:
expression during infection with the acute strain MNV-1 in two permissive
cell lines, a murine macrophage cell line, RAW264.7, and a murine
microglial cell line, BV-2. By RT-qPCR, we further confirmed and analysed
the changes in miR-155 expression in the infected cell lines, bone-marrow
derived macrophage, and tissues harvested from mice infected with the
persistent strain MNV-3. Using miR-155 knockout (KO) mice, we
investigated whether loss of miR-155 affected viral replication and
pathogenesis during persistent MNV-3 infection in vivo and monitored
development of a serum IgG response by ELISA.
We identified cell-specific panels of miRNAs whose expressionResults: 
were increased or decreased during infection. Only two miRNAs, miR-687
and miR-155, were induced in both cell lines. miR-155, implicated in innate
immunity, was also upregulated in bone-marrow derived macrophage and
infected tissues. MNV-3 established a persistent infection in miR-155
knockout (KO) mice, with comparable levels of secreted virus and tissue
replication observed as for wildtype mice. However, serum anti-MNV IgG
levels were significantly reduced in miR-155 KO mice compared to wildtype
mice.
 We have identified a panel of miRNAs whose expressionConclusions:
changes with MNV infection. miR-155 induction is a marker of MNV
infection in vitro and in vivo, however it does not contribute to the control of
persistent infections in vivo. This finding suggests that the immune defects
associated with miR-155 deletion, such as lower serum IgG levels, are also
not important for control of persistent MNV-3 infection.
Keywords
norovirus, MNV, microRNA, miR-155, persistent infection
1,2 1 1
1
2
   Reviewer Status
  Invited Reviewers
 version 1
published
18 Apr 2018
 1 2
report report
, University of Washington,Charlie C. Hsu
Seattle, USA
1
, KU Leuven, Leuven,Dirk Jochmans
Belgium
2
 18 Apr 2018,  :42 (First published: 3
)https://doi.org/10.12688/wellcomeopenres.14188.1
 18 Apr 2018,  :42 (Latest published: 3
)https://doi.org/10.12688/wellcomeopenres.14188.1
v1
Page 1 of 13
Wellcome Open Research 2018, 3:42 Last updated: 15 MAY 2019
  Lucy Thorne ( )Corresponding author: l.thorne@ucl.ac.uk
  : Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing –Author roles: Thorne L
Review & Editing;  : Investigation;  : Investigation;  : Conceptualization, Funding Acquisition, Supervision, Writing –Lu J Chaudhry Y Goodfellow I
Review & Editing
 No competing interests were disclosed.Competing interests:
 This work was supported by the Wellcome Trust [106079], Sir Henry Wellcome Postdoctoral Fellowship to LT, and [097997Grant information:
and 207498], Wellcome Trust Senior Fellowships to IG.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 © 2018 Thorne L  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Thorne L, Lu J, Chaudhry Y and Goodfellow I. How to cite this article: miR-155 induction is a marker of murine norovirus infection but
 Wellcome Open Research 2018,  :42 (does not contribute to control of replication  [version 1; peer review: 2 approved]in vivo 3
)https://doi.org/10.12688/wellcomeopenres.14188.1
 18 Apr 2018,  :42 ( ) First published: 3 https://doi.org/10.12688/wellcomeopenres.14188.1
Page 2 of 13
Wellcome Open Research 2018, 3:42 Last updated: 15 MAY 2019
Introduction
Noroviruses belong to the Caliciviridae family of small, posi-
tive strand RNA viruses. Human noroviruses (HuNoVs) are a 
major cause of viral gastroenteritis worldwide, causing around 
2–3 million infections in the UK every year1. The majority of 
infections are acute and occur in large outbreaks that sweep 
through places with close living environments, such as hospitals, 
at a considerable cost to the NHS2. Although mortality rates are 
generally low, immunocompromised individuals are highly 
susceptible to HuNoV, often developing chronic infections, 
which represent a significant burden of morbidity in transplant 
recipients3.
Until very recently, HuNoVs had remained refractory to all 
attempts to establish a cell culture system. The recent demonstra-
tion of HuNoV replication in enteric organoids4 and a cultured 
B cell line5 represent significant breakthroughs. However, 
understanding of norovirus replication and in particular its 
interactions with the host cell currently still lags behind that of 
other viruses. As an alternative model system, murine norovirus 
(MNV) has been widely used to characterise norovirus 
replication. Like HuNoV, it is an enteric virus, which trans-
mits by the faecal-oral route, and it has been found in wild and 
laboratory mice6,7. It remains the only norovirus that replicates 
in cell culture to produce high titres of infectious virus and has 
a tropism for macrophage, dendritic cells, B and T cells, with a 
recent study also identifying a role of enterocytes in vivo5,6,8,9. 
This, combined with the availability of reverse genetics 
systems10–12 and strains that cause both acute and persistent 
infections in the natural host6,11, makes MNV a valuable model 
for characterising norovirus-host interactions.
MicroRNAs (miRNAs) are short non-coding RNAs, which 
post-transcriptionally silence over 50% of human mRNAs to 
fine-tune protein expression, contributing to the regulation of 
diverse cellular processes13,14. Interactions with the cellular 
miRNA repertoire have been shown for a diverse range of 
viruses, including RNA, DNA, acute and persistent viruses. 
miRNAs  have been reported to either promote or inhibit viral 
replication, in general by indirectly regulating expression of cel-
lular cofactors or the immune response respectively15,16, although 
direct interactions with viral RNAs have also been reported17,18. 
As such a number of viruses actively manipulate cellular 
miRNA levels, either specifically or by targeting the miRNA 
processing machinery to initiate a global shutdown in miRNA 
biogenesis19–21. Identifying the changes in miRNA expression 
that occur with infection can reveal new proteins or pathways 
that play a role in viral lifecycles.
To date there have been no reports on the interaction between 
noroviruses and the cellular miRNA machinery. Here, we 
aimed to determine whether MNV infection causes changes in 
miRNA expression in permissive cell lines, and whether any of 
the observed effects contribute to viral pathogenesis and affect 
the outcome of infection in vivo.
Methods
Cells
Murine macrophage cell lines RAW264.7 and microglial cell 
line BV-2 (provided by Jennifer Pocock, University College 
London) were maintained in Dulbecco’s modified Eagles Medium 
(DMEM, Gibco) containing 10% fetal calf serum (FCS), peni-
cillin (P) (100 SI units/mL) and streptomycin (S) (100 μg/mL) 
and 10 mM HEPES (pH7.6) at 37°C with 10% CO2. For virus 
recovery BHK cells engineered to express T7 RNA polymerase 
(BSR-T7 cells, obtained from Karl-Klaus Conzelmann, Ludwid 
Maximillians University, Munich, Germany) were maintained 
in DMEM containing 10% FCS, penicillin (100 SI units/mL) 
and streptomycin (100 μg/mL) and 0.5 mg/mL G418. For prepa-
ration of bone marrow derived macrophage (BMDM), bone 
marrow cells were harvested from female C57BL/6 mice and 
were cultured in DMEM containing 10% fetal calf serum (FCS), 
penicillin (100 SI units/mL) and streptomycin (100μg/mL). For 
differentiation the supernatant from CMG14 cells, which 
contains macrophage colony stimulating factor (M-CSF), was 
added to the media for 5–7 days.
Virus recovery and infection
Recombinant viruses were rescued from cDNA clones 
containing either the MNV-110 or MNV-3 genomes11 using 
the reverse genetics system based on recombinant Fowlpox 
expressing T7 RNA polymerase, as previously described10. Fifty 
percent tissue culture infectious dose (TCID50) titrations were 
performed on RAW264.7 and BV-2 cells. For miRNA analysis, 
cell lines were infected with an acute strain of MNV (MNV-1) 
at an MOI of 0.1 TCID50/cell, or were mock infected. BMDM 
were infected with MNV-1 at an MOI of 10 TCID50/cell (as 
determined in RAW264.7 cells).
microRNA extraction and analysis
To analyse miRNA expression the small cellular RNA fraction 
(less than 200nt) was harvested at 20 hpi from cell lines, and 
24 hpi from BMDMs, using the miRVana RNA isolation kit, as 
per manufacturer’s instructions. For cDNA synthesis the Taqman 
miRNA reverse transcription kit was used (Life Technolo-
gies), according to manufacturer’s instructions. 1000 ng of RNA 
extracted from infected and uninfected RAW264.7 cells and 
BV-2 cells were used with Megaplex RT primers, Rodent Pool 
A (Life Technologies). The pool contains primers specific to 
335 and 238 mature unique mouse and rat miRNAs respectively, 
alongside primers for 4 specific endogenous controls. The 
cDNA was then used for qPCR using Taqman Rodent miRNA 
Array A cards (TDLA, Life Technologies, as per manufacturer’s 
instructions), which contain primer-probe sets specific for 381 
rodent miRNAs. The TLDA cards were run on the 7900HT T 
Fast Real-Time PCR System and the data was visualised and 
analysed for the Ct value of each miRNA by RQ manager soft-
ware (Life Technologies). Further analysis was performed using 
Microsoft Excel. The Ct value for each miRNA was normalised 
against the Ct value for the endogenous control small nuclear 
RNA, U6, which did not change with infection. A two-fold 
change was used to indicate a significant change, as suggested 
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in the manufacturer’s instructions. RT-qPCR was also performed 
using individual RT and PCR primer-probes specific to miR-155.
In vivo studies
For analysis of miR-155 expression, three-to-four week old 
female C57BL/6 mice were inoculated with 1000 TCID50 of 
MNV-3 by oral gavage. Each group contained 3 mice and a 
control group was mock infected. The mesenteric lymph node 
(MLN), caecum and colon were isolated on day 2 post infec-
tion (dpi) for RNA extraction. miR-155 knock out mice (Jackson 
Laboratories) and wild type control C57BL/6 mice were 
inoculated with 10 TCID50 of MNV-3 by oral gavage, with 5 
mice in each group. Mice were weighed and faecal samples were 
collected on 1–7, 14 and 21 dpi. Serum samples were col-
lected on days 0 ,7, 14 and 21 pi, and mice were euthanized on 
day 21 pi. Tissue samples were harvested from separate groups 
on day 2 post infection.
RNA extraction and RT-qPCR for viral genome copies
Tissues were homogenised into RNA lysis buffer using ceramic 
beads (BioSpec Products) with a Fast Prep-24 homogeniser 
(MP Biomedicals). Faecal pellets were homogenised in PBS 
(100mg/mL), followed by centrifugation at 4000 rpm for 5 min, 
4°C. RNA was extracted from 100 μL of supernatant using the 
GenElute total mammalian RNA kit (Sigma). Quantification of 
viral genome copies was performed by two-step RT-qPCR, with 
reverse transcription using with M-MLV RT (Promega) with 
random hexamers, as per manufacturer’s instructions. qPCR 
was then performed on the cDNA using a Taqman Low Rox 
qPCR mastermix (Primer design), with primers (MNV-3 F: 
CCGCAGGAACGCTCAGCAG and R: GGCTGAATGGGGACG-
GCCTG), and probe (ATGAGTGATGGCGCA). The ViiaTM 
7 Real time PCR machine was used with an initial denatura-
tion step of 8 min at 95°C, followed by 50 cycles of 95°C for 
10 s and 60°C for 1 min. The genome copy number was inter-
polated from the standard curve and was calculated per ng 
of RNA or per mg of stool depending on the sample, using 
Microsoft Excel. All graphs were produced using Graph Pad 
Prism V.5 Software.
ELISA for serum anti-MNV IgG
We performed ELISAs for detecting MNV-specific serum IgG 
in peripheral blood as previously reported (Hwang et al., 2014, 
Wobus et al., 2004). Briefly, MNV-3 virus-like particles (VLPs), 
kindly provided by Stephanie Karst (University of Florida, 
Gainsville, USA) were diluted 1:100 using carbonate buffer at 
pH 9.6 and 50 μl of VLPs were used per well to coat the Nunc 
MaxiSorp™ 96-well plate overnight at 4°C. Serum was collected 
as the supernatant after spinning the whole blood at 15,000 x g 
for 5 minutes at 4°C and was used at 1:100 dilution in 50 μl total 
volume. The reactions were developed by adding 100 μl 
1-Step™ Turbo TMB-ELISA Substrate Solution (Life Technolo-
gies) and stopped by adding equal volume of 1N sulphuric acid 
solution. The absorbance at 450 nm were read and normalised 
absorbance were calculated by subtracting the mean absorbance 
of wells without primary antibody. The cutoff of positive results 
was determined as the mean + 3 × standard deviation of mock 
serum absorbance.
Results
To investigate changes in miRNA expression with norovirus 
infection, we infected two permissive cell lines, a murine 
macrophage cell line, RAW264.7, and a murine microglial cell 
line, BV-2, with an acute strain of MNV (MNV-1). We ana-
lysed miRNA expression at 20 hours post infection (hpi), a time 
selected to coincide with the peak in innate immune responses 
against MNV-1 previously identified22, as many macrophage 
miRNAs are thought to be involved in regulating interferon 
(IFN) responses23. We found that only a small panel of miR-
NAs had altered expression as a result of MNV-1 infection in 
both RAW264.7 and BV-2 cells, whereas the majority did not 
change by more than 2-fold (Figure 1A). In total 6 miRNAs were 
upregulated by more than 2-fold in RAW264.7 cells: miR-
687 (20.5x), miR-155 (10.5x), miR345-5p (5.5x), miR-658 
(4.5x), miR-132 (3.1) and miR-210 (2.6x). In contrast, 5 miR-
NAs were downregulated in infected BV-2 cells: miR-let7b 
(4.0x), miR-207 (3.9x), miR-146a and miR-744 (both 2.1x), 
and miR-17 which was highly expressed in uninfected cells and 
decreased to below the level of detection with infection, repre-
senting the greatest change in BV-2s (Figure 1B). Taken together 
these results indicate cell-specific responses to viral infec-
tion. The only common response was the induction of miR-687 
and miR-155, which were also upregulated in both cell lines 
but to a lesser extent in BV-2 cells than in RAW264.7 cells 
(6.1x and 2.0x respectively), (Figure 1B).
miR-155 is one of the most well-characterised miRNAs, 
with known links to innate immunity and an antiviral 
response24,25. We therefore focused on miR-155, hypothesis-
ing that the increase in miR-155 may contribute to or potentially 
regulate the antiviral response to MNV infection. We first 
validated miR-155 induction in infected RAW264.7 and BV-2 
cells using RT-qPCR. Compared to the data obtained using 
qPCR-based arrays, we detected an even greater increase in 
miR-155 expression in both infected cell types at the same time 
point post infection, with an induction of 100x in RAW264.7 
cells (Figure 1A and Figure 2A). Also in line with the array data, 
miR-155 was more highly induced in infected RAW264.7 cells 
compared to infected BV-2s (Figure 2A), despite MNV-1 attain-
ing similar levels of replication in both cell types (Figure 2B). 
We further validated the induction of miR-155 in MNV-1-
infected bone-marrow derived macrophage cells (BMDMs). 
miR-155 expression was induced approximately 20-fold at 24 
hpi in BMDMs, which rose to approximately 60-fold at 48 hpi 
(Figure 2C).
To determine whether miR-155 is upregulated during MNV 
infection in vivo, we infected immunocompetent mice with 
the persistent MNV-3 strain, and harvested tissues at day 2 post 
infection. This timing coincides with the peak in viral loads 
during the acute phase of infection, when virus can be detected 
in the caecum, colon and mesenteric lymph node (MLN)11. We 
found that miR-155 was significantly increased in the caecum, 
the primary site for MNV replication11, and a trend for induc-
tion was observed in the colon and MLN, although this was not 
significant.
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Figure 1. Changes in miRNA expression with MNV-1 infection in two permissive cell lines. (a) Murine macrophage RAW264.7 cells 
(b) murine microglial BV-2 cells were infected with MNV-1 at an MOI of 0.1 TCID50/cell. The small RNA fraction was harvested at 20 hpi. 
Reverse transcription was performed using a set of primers specific for 380 miRNAs, followed by qPCR analysis using TLDA miRNA cards. 
The relative quantity value on the y-axis is equivalent to fold change. The dashed lines indicate a 2-fold increase and decrease, above or 
below which the change is considered significant.
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Figure 2. miR-155 is upregulated in MNV-infected cells and tissues. (a) The fold change in miR-155 mature transcript levels with MNV-1 
infection in RAW254.7 cells and BV-2s (0.1 TCID50/cell) at 20 hpi. (b) MNV-1 replicates to similar levels in RAW264.7 cells as BV2 cells. Viral 
titres were determined by TCID50. (c) miR-155 is upregulated over a time course of infection of MNV-1 in BMDMs. (d) miR-155 expression is 
induced in tissues infected with MNV-3 harvested at day 2 post infection from wildtype mice.
To determine whether miR-155 contributes to an antiviral 
response, we infected wildtype (WT) and miR-155 knockout 
(KO) mice with MNV-3. We choose to assess the role of miR-155 
in a persistent model of infection as a recent study showed that 
miRNAs play a greater role in chronic infections than in acute 
infections, through regulating the expression of pro-inflammatory 
cytokines26. MNV-3 typically causes a sub-clinical persistent 
infection in wildtype (WT) C57BL/6 mice11. Similarly, we did 
not observe any weight loss in miR-155 KO mice, indicating 
that there was no increase in disease severity (data not shown). 
Accordingly, MNV-3 was secreted at similar levels in the KO 
and WT mice throughout 21 days of a persistent infection 
(Figure 3A). We harvested tissues at day 2 post infection to 
investigate if the lack of miR-155 affected dissemination of 
the virus, but we observed no difference in viral genome cop-
ies in the colon, caecum or ileum (Figure 3B). Altogether 
this suggested that miR-155 does not play an essential role in 
controlling MNV replication in the acute or persistent phases of 
infection.
To determine whether miR-155 had any impact on the adaptive 
immune response to MNV-3, we compared development of the 
serum anti-MNV IgG response in infected miR-155 KO and 
WT mice. We found there was a lag in the production of serum 
IgG in the miR-155 KO mice, which had significantly lower 
levels compared to the WT mice at days 14, 21 and 28 hpi. Over 
this time course of the infection, the levels of serum IgG in the 
miR-155 KO mice did not reach those observed in WT mice.
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Figure 3. MNV-3 persistence and replication is not affected in miR-155 KO mice. (a) MNV-3 is secreted at similar levels in the faeces 
from miR-155 KO mice as WT mice over the course of a persistent infection. (b) MNV-3 dissemination and replication in the tissues was 
comparable in miR-155 KO mice and WT mice at day 2 post infection. LOD indicated limit of detection. (c) miR-155 KO mice have impaired 
serum anti-MNV IgG levels compared to WT mice.
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Discussion
In summary, we have identified a panel of miRNAs whose 
cell-type specific expression changes with MNV infection, 
indicating that MNV infection does not initiate a global shut-off 
in miRNA expression. miR-155 induction appears to be a marker 
of MNV infection in two permissive cell lines, as well as BMDMs 
and in vivo in infected tissues. However, the absence of miR-
155 did not impact the course of infection or viral replication 
during persistent infection in vivo. This finding suggests that 
the immune defects associated with miR-155 deletion, such as 
lower serum IgG levels, are not important for control of persistent 
MNV infections.
miR-155 is one of the most highly studied miRNAs, upregu-
lated in different cancers and with diverse cell-type specific 
roles reported27,28. In macrophage, miR-155 has been associated 
with the innate antiviral response, as it is induced as a result of 
signaling through the RIGI/JNK/NF-κB pathway24. Upregula-
tion of miR-155 promotes type I IFN signaling by silencing the 
negative regulator of the pathway, suppressor of cytokine sign-
aling 1, (SOCS1)24. Increased expression of miR-155 has also 
been shown to be accompanied by increased expression of 
pro-inflammatory mediators29. As part of an inflammatory response 
the expression of miR-155 can also be increased indirectly 
through miR-342-5p29, which was also induced in infected 
RAW264.7 cells and may have therefore contributed to the 
increase in miR-155 following MNV infection. As we observed 
no impact resulting from the loss of miR-155 on viral replication 
in vivo, in this study we did not further investigate which 
miR-155 targets are silenced in MNV-infected cells. A similar 
pro-inflammatory role has been demonstrated for miR146a in 
microglial cells30, which we found was upregulated in BV-2 cells.
The defect we observed in the serum anti-MNV IgG response 
in miR-155 KO mice is consistent with their reported immune 
impairment, including defective TNFα production, reduced 
T-cell dependent antibody responses and a decrease in the 
proportion of INFγ-producing cells31. Interestingly, this suggests 
that the serum IgG response and these other aspects of the 
immune response do not play a role in controlling persistent 
MNV infections in vivo, as despite the impaired responses, MNV 
replication was unaffected. This finding is in contrast to a previ-
ous report where antibody responses were proposed to contribute 
to clearance of acute infections, and the control of MNV 
replication in persistently infected mice, although this was per-
formed using mice defective in B cells and RAG1 KO mice32, 
suggesting this may be due to other defects in the antibody 
response than just serum IgG levels.
miR-687 was the most highly induced miRNA in both cell lines 
upon MNV infection, however very little is known about its 
function and expression profile. To date there has only been one 
study on the function of miR-687, which links it to regulation 
of cell cycle progression and apoptosis in kidney cells, through 
regulation of the phosphatase PTEN33. PTEN has recently been 
reported to have a further independent function in regulating 
innate immunity, by controlling activation and nuclear import 
of the master transcription factor governing IFNβ production, 
IRF334. Both apoptosis and IRF3 activation are thought to occur 
during MNV infection35,36, therefore whether miR-687 is involved 
in the regulation or crosstalk between these pathways will be an 
interesting avenue for future studies, which could reveal novel 
functions of miR-687 in the cellular response to viral stress.
In microglial BV-2 cells, downregulation of miR-17 was the 
greatest change associated with MNV infection. Further studies 
are required to validate this change in primary cells and infected 
tissues, but interestingly miR-17 has been shown to regulate 
autophagy through the suppression of Atg7 translation37. Atg7 
is known to be required for the INFγ antiviral response against 
MNV by promoting assembly of a complex of autophagy 
proteins, which in turn prevent formation of the MNV replica-
tion complex, although a direct mechanism linking INFγ and 
Atg7 has not been established38. It is therefore interesting to 
speculate as to whether downregulation of miR-17 could pro-
vide this link, resulting in an increase in Atg7 translation, thereby 
contributing to the IFNγ antiviral response.
Finally, the recently developed organoid4 and B cell culture 
systems5 for HuNoV now provide the opportunity to compare 
the cell-type specific responses in miRNA expression, with the 
aim of identifying novel cellular proteins involved in HuNoV 
replication.
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This manuscript by Thorne et al describes the first investigation on the role of miRNAs in norovirus
infections. They discovered several miRNA’s of which the expression levels significantly change upon
infection with MNV-1 in cell lines, which is a unique contribution to the field. They also show that a
knockout of miR-155 does not influence the replication of MNV-3 in a mouse model. Both these results
are sufficiently innovative to warrant the publication of this paper. In general the paper is well written and
integrates very well the current knowledge on the topic.
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The cell line work has been done using MNV-1 while the animal work was performed with MNV-3.
It is not impossible that the effect of norovirus on miR-155 is only apparent with MNV-1 and not
with MNV-3. This would put the animal work in another perspective. It would therefore be very
informative if the experiments described in fig 2.a, 2.b and 2.c are also performed with MNV-3. This
may clearly demonstrate that also MNV-3 influences miR-155 expression  . Now the onlyin vitro
effect of MNV-3 on miR-155 expression is shown in fig 2.d but in our opinion, this is not sufficiently
convincing to say that the effect is significant. In the first panel of fig 2.d the significance is
indicated by “**” but it is not stipulated what the p value is here.
 
A second topic of discussion is the way the data is presented in figure 1. In our opinion, it is
important to depict the fold change of expression level on a log scale. The expression levels are
determined from Ct values that follow a normal distribution and for which a stdev can be
calculated. If one log-transforms the Ct values to expression levels the normal distribution is lost
and other statistics than stdev should be used. Therefore I would suggest that the authors calculate
for each measurement the log(fold change over mock) and for these values calculate the average
and stdev and show these on the y-axis of fig 1. This would also give a more clear presentation of
the data around the 2-fold increase/decrease expression level. It would also benefit the reader
significantly to plot the miR in a specific order and to put the expression of one miR in both cell
lines next to each other. At this moment the reader cannot easily compare the expression levels of
a particular miR between the cell lines.
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In figure 1 the number of measurements are not indicated
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 In figure 1 the number of measurements are not indicated
 
In the methods the manufacturer of the miRVana kit is not indicated
 
In the first paragraph of the results section, the average values of the expression levels are
indicated but not the statistics. An average of the log(fold change) and stdev could be indicated
instead (see topic 2 above). The conclusion that miR-155 is upregulated in BV-2 cells is now
difficult to conclude from fig 1.
 
In the third paragraph of the result section the authors should refer to fig 2D
 
In fig 3 LOD stands for limit of detection. Perhaps the authors mean limit of quantification?
 
When referring to reference 32 in the conclusion the authors may want to comment that this was a
paper studying MNV-1 and not MNV-3. It can be that IgG play a role in MNV-1 infections but not
MNV-3 infections and vice versa for miR-155.
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The manuscript “miR-155 induction is a marker of murine norovirus infection but does not contribute to
control of replication  ” by Thorne et al. is a well written report describing the impact of MNV infectionin vivo
on microRNAs both   and  .  The reported findings are novel in that this is the first reportin vitro in vivo
evaluating the interaction of noroviruses and miRNAs.  The authors show that MNV indeed can modulate
miRNA expression in cell lines, BMDM, and  .  They report that miR-155, a microRNA involved within vivo
type I interferon signaling, is upregulated both   and  , but that miR-155 knockout mice did notin vitro in vivo
show any differences in viral replication compared to infected wild-type mice despite having lower serum
anti-MNV antibody levels.  These results suggest that miR-155 does not significantly contribute to control
of MNV replication.  This manuscript is well organized and the authors do a nice job explaining their
rationale for the experiments and they also thoughtfully discuss and interpret their results.
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It is suggested to include the full nomenclature on the C57BL/6 wild-type mice, as well as the
miR-155 knockout mice from Jackson Laboratories in the Methods to provide the readers
information on which C57BL/6 substrain was used, and for accuracy of the miR-155 mouse strain.
 
It would be interesting to see whether lack of miR-155 and the lower anti-MNV antibody levels in
miR-155 knockout mice would impact viral levels and persistence in MNV-1, a typically
non-persistent viral strain.  Although the authors provide an adequate explanation of why they used
MNV-3, a persistent viral strain, for the   study, rather than the MNV-1 that was used  ,in vivo in vitro
this reviewer is curious if the lower antibody levels may perhaps prevent clearance of MNV-1 in
these mice, or if virus persists longer than in WT mice but ultimately gets cleared.  These results
may shed light on the importance (or lack of importance) of miR-155 associated immune defects
on non-persistent viral strain.
 
It is suggested to include information on the statistical tests used to evaluate differences if not
already included in the manuscript.
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